Image Image Image Image Image Image Image Image Image Image
Accessibilité
Haut de page

Up

En quoi nous distinguons-nous des autres? 

Médecine 360º

À la rigueur médicale qui nous caractérise, viennent s’ajouter d’autres prestations pour une prise en charge globale du patient avec un programme de services exclusifs gratuits.

  • Prise en charge psychologique.
  • Conseil en nutrition.
  • Conseil dans les technologies d'assistance.
  • Service d'accompagnement.
Entre autres services. + Voir plus

Actualités + Voir plus

IMG_7393 (retoc)
13/12/2019.
¿Sabes cuáles son las enfermedades minoritarias relacionadas con la visión?
Las enfermedades minoritarias son poco frecuentes, pero numerosas: se...

Actualités

Foto Equip MalatMinoritaries-image3
09/12/2019.
The Institut de la Màcula team joins the call by La Marató de TV3 to spotlight rare diseases
La Marató de TV3, Spain’s top telethon and the one that raises the...

Actualités

20191106_165523
27/11/2019.
Josep Maria Bigorra, a patient with dry eye: “With the IPL Laser, the improvement has been huge”
Josep Maria Bigorra had suffered several bouts of infectious conjunct...

Actualités

amd3
21/11/2019.
Dr Jordi Monés explains the huge impact of atrophic AMD at the Iveric Bio Zymura Investors R&D Science Day
Dr Jordi Monés MD, PhD, the Director of the Institut de la Màcula, ...

Actualités

Recherche + Voir plus

talon
26/11/2019.
TALON clinical trial: Efficacy and safety of brolacizumab in the treatment of exudative AMD

 

IF YOU WANT TO PARTICIPATE IN A CLINICAL TRIAL, SEND US YOUR DATA HERE AND WE WILL EVALUATE IF YOU ARE ELEGIBLE

Description

Multicentre, randomised double-blind Phase IIIb study to evaluate the efficacy and safety of brolacizumab 6mg compared to aflibercept 2mg in a treatment regimen until control in patients with the exudative form of age-related macular degeneration (AMD).

Main inclusion criteria

Patients of 50 and above with an active choroidal neovascularisation secondary to AMD and who have not received any previous treatment in the study eye.

Visual acuity should be between 38 and 83 letters (approximate Snellen equivalent of 20/25 to 20/200).

Aims

To evaluate the efficacy and safety of brolacizumab in comparison with aflibercept with regard to the results for visual acuity at 28 and 32 weeks in reference to the baseline, but also in terms of the duration of the intervals between treatments.

About the drug

Vascular endothelial growth factor (VEGF) is a glycoprotein with a trophic and proliferative role, promoting the growth of new filtering and abnormal blood vessels in the retina in patients with exudative AMD.

Brolacizumab (RTH258) is a humanised single-chain antibody fragment (scFv) that is responsible for blocking the action of VEFG-A, preventing it from binding to its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, meaning that its principal function is anti-angiogenic. Brolacizumab is designed for ophthalmic use and administered by intravitreal injection.

Previous studies have produced results that support the commencing of a Phase IIIb trial in order to evaluate the safety and efficacy of brolacizumab in patients with neovascular AMD, with the aim of prolonging the therapeutic effect and enabling improved penetration of retinal tissue.

Duration

The duration of this trial is sixteen months.

* Institut Registration Code: E08607500. Clinica trial n. EudraCT 2019-000716-28. Clinical trial authorised by the Spanish Agency of Medicines and Medical Devices (AEMPS) and the CEIm of the Quironsalud Hospital Group in Barcelona.

IF YOU WANT TO PARTICIPATE IN A CLINICAL TRIAL, SEND US YOUR DATA HERE AND I WIY EVALUAREMOS SI ERES ELEGIBLE

 IDLM-53_2

...

Recherche Recrutement

IM_Captura-4-1024x681
13/11/2019.
Research project MICROBEYEOME

 

IF YOU WANT TO PARTICIPATE IN A CLINICAL TRIAL, SEND US YOUR DATA HERE AND WE WILL EVALUATE IF YOU ARE ELEGIBLE

Description

Age-related macular degeneration (AMD) is the leading cause of vision loss in people of over 50 in developed countries. Although the risk factors for the disease have been widely catalogued, its causes continue to be little known.

In recent years, there has been an exponential increase in research on the association between the intestinal microbiota and the diseases that affect humans.

Principal inclusion criteria

Patients of over 50, with age-related macular degeneration and healthy patients.

The patients must not have taken antibiotics in the past three months.

Patients with other neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, or those in treatment for any type of cancer, will be excluded.

Aim

The MICROBEYEOME study attempts to characterise the intestinal and oral microbiome of the patients diagnosed with AMD through RNA 16S sequencing and compare it with the microbiome of healthy patients, thereby identifying whether a single microbial composition may be associated with a specific phenotype. Given that the intestinal microbiome is potentially modifiable, this study could open new avenues of research for the prevention and/or possible treatment of AMD.

Duration

This initial phase of the trial consists of a single visit.

Consortium partners

Institut de la Màcula
Barcelona Macula Foundation
 Centre for Genomic Regulation

 

...

Recherche Recrutement

DMAE exsudativa (1)
09/04/2019.
LUCERNE clinical trial: efficacy and safety of FARICIMAB regarding aflibercept in the treatment of exudative age-related macular degeneration

IF YOU WANT TO PARTICIPATE IN A CLINICAL TRIAL, SEND US YOUR DATA HERE AND I WILL EVALUATE IF YOU ARE ELIGIBLE

Description

This is a multicentre, randomized and double-masking Clinical Trial Phase III of two parallel groups that evaluates the efficacy and safety of faricimab administered by intravitreal injeccions in patients with exudative age-related macular degenereation (AMD) compared to treatment with aflibercept (EYLEA®).

 Main inclusion criteria

Patients over 50 years of exudative age-related macular degeneration who have not received study’s treatment for this eye disease

Visual acuity should be between 20/32 and 20/320.

 Goal

The main objective is to demonstrate the efficacy of faricimab compared with aflibercept regarded the visual acuity result one year later

About the medicine

Faricimab is the first bispecific monoclonal antibody designed for intravitreal use that combines the antiangiogenic action of the medicine currently used for the AMD’s treatment with the anti-inflammatory action, neutralizing VEGF and angiopoietin-2 at the same time. The results in previous studies support the beginning of a Phase III trial to evaluate the efficacy and safety of faricimab in the treatment of neovascular AMD patients, in order to increase the intervals between treatments.

 Duration

This essay lasts for two years.

IF YOU WANT TO PARTICIPATE IN A CLINICAL TRIAL, SEND US YOUR DATA HERE AND I WILL EVALUATE IF YOU ARE ELIGIBLE

...

Recherche

AGF-DME
03/03/2019.
RHINE – Phase III study in the treatment of diabetic macular oedema

IF YOU WANT TO PARTICIPATE IN A CLINICAL TRIAL, SEND US YOUR DATA HERE AND I WILL EVALUATE IF YOU ARE ELIGIBLE

Description:

This is a phase III, multi-centre, randomised, double-masked, three-group trial that assesses the efficacy and safety of RG7716 administered through intravitreal injections in adult patients with visual disturbance due to diabetic macular oedema (DMO) in comparison with the administration of aflibercept (EYLEA®).

Principal inclusion criteria:

Patients of over 18 years of age with type 1 or 2 diabetes mellitus and visual disturbance due to diabetic macular oedema in the study eye without previous treatment with any anti-VEGF drug or who have not received it in the past three months.

Visual acuity should be between 20/32 and 20/320.

Aim:

The main aim is to demonstrate that RG7716 is not inferior to aflibercept with respect to visual outcome after the first year of treatment.

About the drug:

RG7716 is an antibody that inhibits for the first time and simultaneously two factors, VEGF-A and Angiopoietin 2, producing a priori improved control of the mechanisms that induce diabetic macular oedema.

Duration:

This trial has a duration of two years.

*Institut Registration Code: E08607500. Clinical trial authorised by the Spanish Agency of Medicines and Medical Devices (AEMPS) and the CEIm of the Quironsalud Hospital Group in Barcelona.

IF YOU WANT TO PARTICIPATE IN A CLINICAL TRIAL, SEND US YOUR DATA HERE AND I WILL EVALUATE IF YOU ARE ELIGIBLE

...

Recherche

Patients internationaux

Vous ne résidez pas à Barcelone et souhaitez vous faire soigner à l'Institut de la Màcula ? Cliquez ici . Vous trouverez toutes les informations dont vous avez besoin.

Aidez-nous à stopper les maladies dégénératives de l’œil. La BMF se consacre à la recherche de traitements capables d’inverser de plus en plus de formes de cécité. Collaborez avec la Barcelona Macula Foundation: Research for Vision

BMF-transp
Last modified: 13 December, 2019 - 21:14